AxoGen, Inc.
AXGN
Rank in Stocks
#4633
AxoGen, Inc., along with its subsidiaries, specializes in creating and... AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Share Price
$50.64
Last synced: 2026-11-09
Market Cap
$3.02B
Change (1 day)
1.24%
Change (1 year)
107.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AxoGen, Inc. (AXGN)
Category
Healthcare
Operating Margin for AxoGen, Inc. (AXGN)
Operating Margin as of November 2026 TTM: -5.17%
According to AxoGen, Inc.'s latest financial reports, its current operating margin (TTM) is -5.17%. At the end of 2025 the company had an operating margin of -3.49%.
Operating Margin history for AxoGen, Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -5.17% | 48.14% |
| 2025 | -3.49% | 99.43% |
| 2024 | -1.75% | -87.04% |
| 2023 | -13.50% | -37.03% |
| 2022 | -21.44% | 7.41% |
| 2021 | -19.96% | -3.29% |
| 2020 | -20.64% | -29.87% |
| 2019 | -29.43% | 20.52% |
| 2018 | -24.42% | 85.56% |
| 2017 | -13.16% | -33.47% |
| 2016 | -19.78% | -41.67% |
| 2015 | -33.91% | -41.82% |
| 2014 | -58.28% | -33.49% |
| 2013 | -87.62% | -13.62% |
| 2012 | -101.43% | -29.42% |
| 2011 | -143.70% | -92.90% |
| 2010 | -2,025.27% | -3,262.01% |
| 2009 | 64.05% | -104.41% |
| 2008 | -1,453.41% | 82.48% |
| 2007 | -796.49% | 153.87% |
| 2006 | -313.74% | 325.99% |
| 2005 | -73.65% | 529.49% |
| 2004 | -11.70% | -32.02% |
| 2003 | -17.21% | -52.68% |
| 2002 | -36.37% | 74.69% |
| 2001 | -20.82% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -102.95% |
US
|
|
| 18.08% | -103.50% |
IE
|
|
| 21.25% | -104.11% |
US
|
|
| 21.05% | -104.07% |
US
|
|
| 28.09% | -105.43% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about AxoGen, Inc.'s operating margin
What is AxoGen, Inc.'s operating margin?
AxoGen, Inc.'s operating margin is -5.17%, as of Nov 2026.
What was AxoGen, Inc.'s operating margin in 2025?
In 2025, AxoGen, Inc.'s operating margin was -3.49%, compared with -1.75% in 2024.
How has AxoGen, Inc.'s operating margin changed since 2020?
From 2020 to 2025, AxoGen, Inc.'s operating margin was highest in 2024 (-1.75%) and lowest in 2022 (-21.44%).
How does AxoGen, Inc.'s operating margin compare with similar companies?
AxoGen, Inc.'s operating margin (-5.17%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.